Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.71 USD | +0.38% | -5.53% | +91.70% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+91.70% | 728M | D+ | ||
+64.92% | 62.59B | B- | ||
-1.85% | 41.18B | B | ||
+44.76% | 40.29B | A | ||
-8.93% | 27.9B | C | ||
+13.05% | 26.21B | B- | ||
-21.96% | 19.09B | B | ||
+4.21% | 13.08B | B+ | ||
+25.74% | 12.26B | B+ | ||
+27.42% | 12.05B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PRAX Stock
- Ratings Praxis Precision Medicines, Inc.